| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydroxycinnamic acid compounds (p-coumaric, caffeic acid (CA), ferulic acid) occur most frequently as simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the form of glucosides. https://www.sciencedirect.com/topics/chemistry/hydroxycinnamic-acid Hydroxycinnamic acids (HCAs) are plant-derived phenolic acids (including caffeic, ferulic, p-coumaric, and sinapic acids) with documented antioxidant, anti-inflammatory (NF-κB↓), and context-dependent anticancer effects in cellular and preclinical models. Mechanistic themes include activation of the Nrf2/ARE antioxidant response, suppression of pro-inflammatory and survival pathways (such as NF-κB and PI3K/AKT), modulation of MAPK signaling, and downstream effects on cell-cycle, apoptosis, invasion, and angiogenesis. Oral exposure is influenced by rapid metabolism (phase II conjugates) and food matrix effects, which affects systemic bioavailability and translational relevance. Biological effects vary by specific hydroxycinnamic derivative and its conjugated/esterified form. (Caffeic acid ≠ ferulic acid ≠ sinapic acid) -Ferulic acid and p‐coumaric acid are naturally occurring hydroxycinnamic acids found in many plant-based foods (such as whole grains, fruits, and vegetables) CA showed pro-oxidant potential due to its ability to interact with metals like copper, inducing lipid peroxidation and causing DNA damage within tumor cells through either oxidation or covalent adduct formation. Summary: -HCAs are classically antioxidant -Such as caffeic acid, ferulic acid, and sinapic acid (SA) -May increase sensitivity to chemotherapy -Bioavailability is problem. Formulation strategies (e.g., liposomal or encapsulated forms) are investigated to improve systemic exposure. -Propolis has caffeic acid (Caffeic acid (0.639–4.172 mg/g propolis) -SA at higher concentrations may acts as a potent pro-oxidant agent -SA may act in collaboration with other chemotherapeutic agents to improve treatment sensitivity. -Co-administration of caffeic acid or CAPE with other anti-tumor compounds (e.g., gallic acid) has shown additive or synergistic effects in selected models -Combination of caffeic acid and endogenous copper ions can result in oxidative damage -Ferulic Acid (abundant in whole grains,popcorn): upregulate apoptotic protein and downregulate anti-apoptotic protein.upregulating (BAX), (p53), (CYCS) and downregulating (Bcl-2), Major Hydroxycinnamic Acids and Their Main Mechanisms
Practical grouping: For a class-level Hydroxycinnamic Acid entry, the four core free HCAs are caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid. Chlorogenic acid, rosmarinic acid, and CAPE are chemically related HCA derivatives but have sufficiently distinct pharmacokinetics and biological activity that they are often better maintained as separate database products. Hydroxycinnamic acids — HCAs are a family of plant-derived phenolic acids characterized by a C6-C3 cinnamic-acid backbone bearing one or more hydroxyl/methoxy substituents. Major dietary HCAs include caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid; chlorogenic acids and related esters are important dietary conjugates. HCAs are classified as non-flavonoid polyphenolic phenolic acids and occur widely in coffee, cereals, fruits, vegetables, herbs, and plant-derived foods. They are not a single pharmacologically uniform agent: caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid can differ substantially in potency, redox behavior, metabolism, and molecular targets. Anticancer activity remains predominantly preclinical and should generally be attributed to the specific HCA rather than generalized to the entire class. Primary mechanisms (ranked):
Bioavailability / PK relevance: HCAs are absorbed from the gastrointestinal tract, but the parent aglycones undergo substantial intestinal, hepatic and microbiome metabolism, particularly glucuronidation, sulfation, methylation and hydrogenation. Circulating exposure therefore consists substantially of conjugated and microbial metabolites rather than unchanged parent compound. Food matrix, esterification and site of intestinal release materially alter exposure. Pharmacokinetic reviews indicate that systemic parent-HCA concentrations after dietary intake are generally in the submicromolar-to-low-micromolar range, with one recent systematic assessment reporting maximal blood concentrations around 0.4 µM for cinnamic-acid derivatives such as caffeic/ferulic acid in the datasets examined. Formulation approaches including nanoparticles and encapsulation are being investigated to increase exposure. In-vitro vs systemic exposure relevance: Many reported direct anticancer effects use tens to hundreds of micromolar HCA concentrations. For example, ferulic acid produced IC50 values of approximately 300 µM in PC-3 and 500 µM in LNCaP prostate cancer cells. These concentrations greatly exceed typical circulating concentrations attainable from ordinary dietary exposure. Consequently, direct tumor-cell cytotoxicity demonstrated at high in-vitro concentrations should not be interpreted as evidence that dietary HCAs achieve equivalent systemic anticancer exposure. Metabolites, local gastrointestinal exposure, chronic signaling effects and specialized formulations may have different pharmacological relevance. Clinical evidence status: Preclinical for cancer treatment. There is substantial cell-culture evidence and some animal-tumor evidence for individual HCAs, especially ferulic and caffeic acids, but no established HCA-class anticancer therapy and no convincing randomized human evidence demonstrating treatment of established cancer with isolated HCAs. Human studies more commonly concern dietary exposure, cardiovascular/metabolic effects, pharmacokinetics, skin photoprotection or complex HCA-containing foods/extracts. HCAs should therefore be classified as experimental/preclinical anticancer agents rather than clinical adjuncts. Hydroxycinnamic Acid Cancer Mechanisms
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr Alzheimer’s disease: Hydroxycinnamic acids have preclinical neuroprotective relevance, particularly caffeic and ferulic acids. Reported mechanisms include suppression of Aβ-associated oxidative stress and neuroinflammation, enhancement of endogenous antioxidant defenses, modulation of CREB/neurotrophic signaling, and possible effects on amyloid- and tau-associated pathology. Evidence is primarily cellular and animal-based; convincing clinical evidence that isolated HCAs prevent or treat Alzheimer’s disease is lacking. Rapid metabolism, low parent-compound systemic exposure and uncertain brain exposure remain important translational constraints. Hydroxycinnamic Acids in Alzheimer’s Disease
|
| Source: HalifaxProj(inhibit) |
| Type: |
| Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals. -Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis. -COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors. COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers. The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression: Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways. Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer. Drugs specifically targeting COX-2, such as celecoxib, have been developed. COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS. |
| 1638- | HCAs, | Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications |
| - | Review, | Nor, | NA |
| 1649- | HCAs, | Anticancer Properties of Hydroxycinnamic Acids -A Review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:95 Target#:66 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid